摘要
目的探究老年肺炎患者采用哌拉西林舒巴坦与左氧氟沙星联合用药方案对病症改善的作用。方法方便选取2019年1月—2021年1月收治的88例老年肺炎患者作为研究对象,按随机数字法进行分组,其中对照组44例接受左氧氟沙星单药治疗,研究组44例采用哌拉西林舒巴坦联合左氧氟沙星治疗方案,比较两组疗效、改善症状所用时间、治疗前后血气指标、肺功能指标及用药后不良反应发生率。结果临床疗效比较结果中,研究组总有效率为95.45%,高于对照组81.82%,差异有统计学意义(χ^(2)=4.062,P<0.05);研究组患者接受联合药物治疗后,咳嗽、咳痰、气促、肺部啰音症状改善时间均明显短于对照组,差异有统计学意义(P<0.05);两组患者PaO_(2)水平、血氧饱和度治疗后均高于治疗前,而PaCO_(2)水平低于治疗前,且研究组患者治疗后PaO_(2)水平、血氧饱和度均显著高于对照组,PaCO_(2)水平显著低于对照组,差异有统计学意义(P<0.05);治疗前,两组FEV1、FVC、FEV1/FVC肺功能指标差异无统计学意义(P>0.05),治疗后,两组患者肺功能指标FEV1、FVC、FEV1/FVC均提升,且研究组患者肺功能指标FEV1、FVC、FEV1/FVC显著高于对照组,差异有统计学意义(P<0.05);研究组不良反应发生率为6.82%,对照组不良反应发生率为4.55%,差异无统计学意义(χ^(2)=0.000,P>0.05)。结论老年肺炎用药方案选择哌拉西林舒巴坦与左氧氟沙星合用,疗效理想,不良反应少。
Objective To explore the effect of piperacillin and sulbactam combined with levofloxacin on the improvement of senile pneumonia patients.Methods From January 2019 to January 2021,88 elderly patients with pneumonia were conveniently selected as the research objects,and were grouped according to the random number method.Among them,44 patients in the control group received levofloxacin monotherapy,and 44 patients in the study group received piperacillin and sulbactam combined with levofloxacin treatment plan.Compared the efficacy of the two groups,the time it takes to improve symptoms,blood gas indicators before and after treatment,lung function indicators,and the incidence of adverse reactions after medication.Results In the comparison of clinical efficacy,the total effective rate of the study group was 95.45%,which was higher than 81.82%of the control group,the difference was statistically significant(χ^(2)=4.021,P<0.05);the improvement time of symptoms,shortness of breath,and pulmonary rales was significantly shorter than that of the control group,and the difference was statistically significant(P<0.05);PaO_(2) levels and blood oxygen saturation of the two groups of patients after treatment were higher than before treatment,while PaCO_(2) levels lower than before treatment,and the PaO_(2) level and blood oxygen saturation of the study group after treatment were significantly higher than the control group,and the PaCO_(2) level was significantly lower than the control group,the difference was statistically significant(P<0.05);before treatment,the FEV1,FVC,FEV1/FVC pulmonary function indexes of the two groups were not statistically different(P>0.05),after treatment,the pulmonary function indexes FEV1,FVC,FEV1/FVC of the two groups increased,and the pulmonary function indexes FEV1,FVC,FEV1/FVC in the study group was significantly higher than that of the control group,and the difference was statistically significant(P<0.05);the incidence of adverse reactions in the study group was 6.82%,and the incidence of adverse
作者
陈大勇
CHEN Dayong(Department of Respiratory Medicine,Dongtai Hospital,Nantong University,Dongtai,Jiangsu Province,224200 China)
出处
《中外医疗》
2021年第33期85-88,共4页
China & Foreign Medical Treatment
关键词
肺炎
左氧氟沙星
哌拉西林舒巴坦
症状改善时间
血气
肺功能
不良反应
Pneumonia
Levofloxacin
Piperacillin and sulbactam
Time to symptom improvement
Blood gas
Lung function
Adverse reactions
